Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
Int J Pharm. 2022 Apr 25;618:121683. doi: 10.1016/j.ijpharm.2022.121683. Epub 2022 Mar 18.
Parkinson's disease (PD) is triggered by the formation of free radicals in dopaminergic neurons, which results in oxidative stress-induced neurodegeneration. The objective of the work was to relieve oxidative stress by employing intranasal delivery of Bromocriptine Mesylate (BRM) and Glutathione (GSH) loaded nanoemulsion for the better management of PD. The depth of permeation of the nanoemulsion was assessed through confocal laser scanning microscopy (CLSM) which revealed higher nanoemulsion permeation in contrast to suspension. Biocompatibility of nanoemulsion was confirmed by nasal cilio toxicity study. The DPPH study showed that the nanoemulsion had significant antioxidant activity. Biochemical estimation studies in Wistar rats were carried out in order to determine the effect of nanoemulsion on oxidative stress. The levels of GSH, superoxide dismutase (SOD), and catalase (CAT) were significantly enhanced; and the level of thiobarbituric acid reactive substances (TBARS) was significantly reduced after the intranasal administration of nanoemulsion in the haloperidol-induced model of PD. Furthermore, the levels of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) were also determined which reduced significantly after the administration of nanoemulsion. The oxidative stress levels were lowered with nanoemulsion, showing the combined antioxidant capability of BRM and GSH. The neuroprotective effect of the prepared nanoemulsion was confirmed by histopathological studies. Pharmacokinetic study revealed a higher concentration of BRM and GSH in the brain of Wistar rats after intranasal administration of nanoemulsion with a higher Brain/Plasma ratio. A higher value of AUC of nanoemulsion in the brain after intranasal administration revealed that BRM and GSH remained in the brain for a longer period due to sustained release from nanoemulsion. According to the findings, BRM and GSH loaded nanoemulsion has the potential to provide a combined and synergistic anti-oxidant effect for efficient management of PD.
帕金森病(PD)是由多巴胺能神经元中自由基的形成引发的,导致氧化应激诱导的神经退行性变。本工作的目的是通过鼻腔内给予甲磺酸溴麦角隐亭(BRM)和谷胱甘肽(GSH)负载的纳米乳液来缓解氧化应激,从而更好地治疗 PD。通过共聚焦激光扫描显微镜(CLSM)评估纳米乳液的渗透深度,结果显示纳米乳液的渗透深度高于混悬液。通过鼻纤毛毒性研究证实了纳米乳液的生物相容性。DPPH 研究表明,纳米乳液具有显著的抗氧化活性。在 Wistar 大鼠中进行了生化评估研究,以确定纳米乳液对氧化应激的影响。纳米乳液鼻腔给药后,GSH、超氧化物歧化酶(SOD)和过氧化氢酶(CAT)水平显著升高,丙二醛(TBARS)水平显著降低。此外,还测定了白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)的水平,纳米乳液给药后这些因子的水平也显著降低。氧化应激水平降低,表明 BRM 和 GSH 具有联合抗氧化能力。通过组织病理学研究证实了制备的纳米乳液的神经保护作用。药代动力学研究表明,纳米乳液鼻腔给药后,Wistar 大鼠脑中 BRM 和 GSH 的浓度更高,脑/血浆比更高。纳米乳液鼻腔给药后脑内 AUC 值更高,表明由于纳米乳液的持续释放,BRM 和 GSH 在脑内停留时间更长。根据这些发现,BRM 和 GSH 负载的纳米乳液有可能提供联合和协同的抗氧化作用,从而有效地治疗 PD。